AbbVie's Bold Leap into Cancer Therapy with $10 Billion ImmunoGen Acquisition

Pharma |

30 November 2023

In a strategic move set to redefine cancer therapy, AbbVie Inc. has announced its acquisition of ImmunoGen, marking a significant leap in the fight against solid tumors, particularly ovarian cancer. This bold venture, valued at approximately $10.1 billion, not only expands AbbVie's solid tumor portfolio but also heralds a new era in cancer treatment with ImmunoGen's flagship therapy, ELAHERE.

Central to this acquisition is ELAHERE (mirvetuximab soravtansine-gynx), an innovative antibody-drug conjugate (ADC) and a first-of-its-kind therapy approved for platinum-resistant ovarian cancer (PROC). Its groundbreaking nature lies in its specificity for targeting the folate receptor alpha (FRα) in cancer cells, a novel approach that has shown meaningful survival benefits in patients with PROC.

Novo Nordisk Boosts Global Drug Supply with $2.3 Billion Expansion in France

AbbVie will buy all ImmunoGen shares at $31.26 each, valuing it at about $10.1B. Approved by both boards, the deal should close by mid-2024, pending shareholder and regulatory approvals.

"The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer."

Expansion Beyond Boundaries

The acquisition is not merely a financial transaction but a strategic collaboration that promises to amplify the potential of ELAHERE. With AbbVie's extensive global infrastructure and expertise in clinical and regulatory affairs, the drug is poised for wider geographical and label expansion. This partnership is expected to transform ELAHERE from a breakthrough therapy into a cornerstone of ovarian cancer treatment, potentially benefiting a larger segment of patients.

"With global commercial infrastructure and deep clinical and regulatory expertise, AbbVie is the right company to accelerate geographic and label expansion, and realize the full potential of ELAHERE as the first and only ADC approved in ovarian cancer," said Mark Enyedy, President and CEO, ImmunoGen. "The addition of ImmunoGen's pipeline, platform, and expertise to AbbVie's oncology portfolio is an exciting opportunity for the combined companies to advance innovation in ADCs. This transaction is the culmination of our 40-year commitment to develop and deliver the next-generation of ADCs and more good days for people living with cancer."

Lilly Expands Injectable Manufacturing Capacity with $2.5 Billion Facility in Germany

A Synergistic Fusion of Expertise and Innovation

The merger of AbbVie's and ImmunoGen's portfolios creates a powerhouse in oncology. ImmunoGen's portfolio, particularly its promising next-generation ADCs, complements AbbVie's growing oncology pipeline. This fusion promises to bring forth groundbreaking treatments across a spectrum of solid tumors and hematologic malignancies, showcasing the transformative power of collaboration in medical science.

The Future Landscape of Cancer Treatment

With ongoing clinical development programs, the future of ELAHERE extends beyond its current applications. The potential expansion into earlier lines of therapy and other large patient segments of the ovarian cancer market over the next 5-10 years could redefine the standard of care in cancer treatment. Moreover, ImmunoGen's pipeline, including the promising IMGN-151 and Pivekimab sunirine, indicates a future where ADCs play a pivotal role in treating various cancers.

AbbVie's acquisition of ImmunoGen is more than a business deal; it's a milestone in cancer therapy. It represents a fusion of expertise and innovation, setting the stage for transformative treatments that could redefine how we approach cancer care.

Novartis and Legend Biotech Strike $1 Billion Deal on CAR-T Therapy for Lung Cancer

About Elahere (mirvetuximab soravtansine-gynx)

ELAHERE is a first-in-class ADC targeting the folate receptor alpha (FRα) with maytansinoid payload DM4, a potent tubulin inhibitor designed to eliminate targeted cancer cells. It received U.S. Food and Drug Administration (FDA) accelerated approval in 2022 for treating FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have undergone one to three prior systemic treatment regimens. Positive Phase 3 results from the MIRASOL confirmatory trial will support a Marketing Authorization Application (MAA) to the European Union and a supplemental Biologic License Application (sBLA) to the U.S. FDA for full approval. Ongoing clinical development programs aim to expand into earlier lines of therapy and access larger patient segments of the ovarian market within the next 5-10 years. ImmunoGen's promising next-generation ADC follow-on pipeline enhances AbbVie's growing oncology pipeline, which includes potentially transformative programs for various solid tumors and hematologic malignancies. ImmunoGen's Phase 1 asset, IMGN-151, is a next-generation anti-FRα ADC for ovarian cancer, with potential for expansion into other solid tumor indications. Pivekimab sunirine, currently in Phase 2, is an anti-CD123 ADC targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer. It has been granted FDA breakthrough therapy designation for the treatment of relapsed/refractory BPDCN.